Patient-Centered Decisions and Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer

Video content above is prompted by the following:

Late-Line Treatment Considerations

Key Themes:

• Clinical trial prioritization
• Recommended as optimal approach when feasible

• Novel antibody-drug conjugates and bispecific antibodies show promise

• Opportunity to access future effective therapies early in development
• Brain metastases management
• T-DXd and tucatinib regimens show efficacy for brain metastases

• Consideration of pan-HER inhibitors like neratinib for central nervous system disease

• Emerging data on targeting HER family receptors (HER1/EGFR, HER3, HER4)
• Patient preferences and quality of life
• Consideration of adverse effect profiles, finances, and treatment scheduling

• Options for oral therapies vs infusions vs subcutaneous injections

• Past adverse effect experiences influence future treatment selections

Notable Insights:

• Dr McCann highlighted: “I think I’m most looking forward to exploring how those triple-positive breast cancer patients who would benefit from an ER-targeted therapy and a HER2-targeted therapy together without a cytotoxic could benefit from all those medications we’re currently using in the hormone receptor–positive, HER2-negative space.”

Dr Vidal concluded: “Clinical trial is no longer a side of the treatment. Clinical trial is an important treatment for every patient you see, regardless; it can be early or late stage.”